ALPROLIX®
[Coagulation Factor IX (Recombinant), Fc Fusion Protein]

PROPHY

TREATING ON YOUR TERMS STARTS HERE

3 WAYS ALPROLIX HELPS YOU STAY AHEAD OF YOUR CONDITION AND ON TOP OF WHAT MATTERS.

In the B-LONG study, adults and adolescents who started infusing on a 10-day individualized prophylaxis regimen with ALPROLIX experienced a median annual spontaneous bleed rate (AsBR) of 0.9 bleeds per year.

In the same study, adults and adolescents infusing on a once-weekly prophylaxis regimen with ALPROLIX experienced a median AsBR of 1.04 bleeds per year.

INDICATION

ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

SELECTED IMPORTANT SAFETY INFORMATION

Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding, or have been told you have inhibitors (antibodies) to Factor IX.

Please see next page for additional Important Safety Information and full Prescribing Information.

1 BLEED AND JOINT BLEED PROTECTION*

ADULTS AND ADOLESCENTS ON A PROPHYLACTIC REGIMEN EXPERIENCED A MEDIAN OF

- **1.38 OVERALL BLEEDS PER YEAR** ON A PROPHY INDIVIDUALIZED INTERVAL (n=26)
- **2.95 OVERALL BLEEDS PER YEAR** ON A PROPHY FIXED WEEKLY INTERVAL (n=61)
- **1 OR FEWER SPONTANEOUS BLEEDS PER YEAR** (n=61)

*ALPROLIX has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.

In the B-LONG study, people infusing prophylactically experienced:

- A median of 0.36 joint bleeds per year on a prophy individualized interval (n=26)
- A median of 1.11 joint bleeds per year on a prophy fixed weekly interval (n=61)
- A median of ~1 or fewer spontaneous bleeds per year on a prophylactic regimen (n=61)

2 EXPERIENCE

WITH OVER 6 YEARS OF EXPERIENCE, ALPROLIX IS AN EXTENDED HALF-LIFE FACTOR IX THERAPY THAT HAS BEEN PRESCRIBED FOR **OVER 1,300 PEOPLE IN THE U.S.**

PRESCRIBED FOR OVER **1300 PATIENTS**

3 DOSING

THE RECOMMENDED ADULT AND ADOLESCENT STARTING REGIMEN IS EVERY **7 OR 10 DAYS WITH THE POTENTIAL TO EXTEND** TO 14 DAYS BASED ON YOUR RESPONSE†

7 DAYS 50 IU/KG

10 DAYS 100 IU/KG

†The recommended starting prophylaxis regimens are either 50 IU/kg once weekly, or 100 IU/kg once every 10 days. In children under 12 years of age, start at 60 IU/kg once weekly. Dosing regimen can be adjusted based on your individual response. More frequent or higher doses may be needed in children <12 years of age, especially in children <6 years of age.

In the B-LONG clinical trial, 54% of people in the individualized prophy arm extended to ≥14-day dosing. The overall median dosing interval on study was 12.5 days. The median interval dosing during the last six months in 26 subjects who were on study for at least nine months was 13.8 days.

Talk to your doctor to see if ALPROLIX is right for you.

ALPROLIX®
[Coagulation Factor IX (Recombinant), Fc Fusion Protein]

NEED TO CHAT? WE'RE HERE.

If you're looking for more reasons to switch to ALPROLIX, we've got you covered. Connect with your CoRe Manager, your local community resource, who can walk you through additional information and answer any questions you may have.

Find your CoRe Manager at ALPROLIX.COM/FINDMYCORE

DON'T BE A STRANGER.

Sign up at ALPROLIX.COM/DISCOVER to get all the latest ALPROLIX news and resources.

Follow us at Facebook.com/ALPROLIX

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

IMPORTANT SAFETY INFORMATION

Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding, or have been told you have inhibitors (antibodies) to Factor IX.

Common side effects of ALPROLIX include headache, abnormal sensation in the mouth, and pain in your side with blood in your urine, which may be a sign of clot formation in the urinary collecting system.

Allergic reactions may occur with ALPROLIX. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: hives, chest tightness, wheezing, difficulty breathing, or swelling of the face.

Redness to the skin at the injection site may also occur.

ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek emergency care if you have symptoms of a possible abnormal blood clot, which may include: chest pain, difficulty breathing, unexpected swelling of an arm or leg with or without pain or tenderness.

Your body can also make antibodies called "inhibitors" against ALPROLIX, which may stop ALPROLIX from working properly.

These are not all of the possible side effects of ALPROLIX. Talk to your healthcare provider right away about any side effect that bothers you or does not go away, or if bleeding is not controlled using ALPROLIX.

Please see the full Prescribing Information.

SANOFI GENZYME

© 2020 Genzyme Corporation. All rights reserved. ALPROLIX is a registered trademark of Bioverativ Therapeutics Inc., a Sanofi company. MAT-US-2018868-V1.0-12/2020